Patients with Resistant Hypertension: Nearly 50% doesn’t take medication

Resistant HypertensionThe DENERHTN trial (Renal Denervation for Hypertension) confirmed the efficacy of renal denervation in addition to antihypertensive standard care in patients with resistant hypertension.

 

This study reports the influence of adherence to treatment to control blood pressure. It included 106 patients with resistant hypertension after four week treatment with indapamide 1.5 mg/day, ramipril 10 mg/day (or irbesartan 300 mg/day) and amlodipine 10 mg/day, randomized to renal denervation and stepped-care of other drugs vs. the same antihypertension treatment.

 

For stepped-care, patients received spironolactone 25 mg/day, bisoprolol 10 mg/day, prazosin 5 mg/day and rilmenidine 1 mg/day, consecutively added at monthly visits if blood pressure was ≥135/85 mm Hg.

 

The number of fully adherent patients (20/40 vs. 21/45), partially non-adherent (13/40 vs. 20/45) and completely non-adherent (7/40 vs. 4/45) to antihypertensive drugs resulted similar between the group randomized to renal denervation and the control group, respectively (p=0.3605).

 

The difference in ambulatory systolic blood pressure between both groups was –6.7 mmHg (p=0.3605) in patients completely adherent and –7.8 mm Hg (p=0.0996) in non-adherent patients.

 

Conclusion

The prevalence of non-adherence to antihypertension drugs at six months was close to 50%, but did not differ between the renal denervation group and the control group. Regardless of adherence to treatment, renal denervation in addition to standard stepped care with antihypertension drugs resulted in greater reduction of blood pressure compared to standard care.

Original Title: Adherence to Antihypertensive Treatment and the Blood Pressure–Lowering Effects of Renal Denervation in the Renal Denervation for Hypertension (DENERHTN) Trial.

Reference: Michel Azizi et al. Circulation. 2016 Sep 20;134(12):847-57.

 

We value your opinion. You are more than welcome to leave your comment, suggestions, or questions here below.

More articles by this author

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

TCT 2024 | PEERLESS: Mechanical Thrombectomy with FlowTriever vs Catheter-Directed Thrombolysis in Intermediate Risk PTE

Pulmonary embolism (PE) continues to be the third cause of cardiovascular mortality. The current clinical guidelines recommend anticoagulation in intermediate risk patients presenting right...

Atherosclerotic Renal Artery Stenosis: To Revascularize or Not

At long term, atherosclerotic renal artery stenosis (RAS) can lead to hypertension, chronic kidney disease, and cardiac failure. Historically, these patients have been referred...

Endovascular Management of Chronic TEPH: Is Coronary Management Extrapolatable in This Scenario?

Chronic thromboembolic pulmonary hypertension (CTEPH) is a condition that causes significant functional limitation. Its surgical treatment, known as pulmonary endarterectomy (PEA), has improved the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...